Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237379 · ClinicalTrials.gov registry record
Peroxisomal Defects and Familial Risk for Bipolar Disorder
A clinical trial, sponsored by University of Cincinnati.
- Completed
- Registry status
- 80
- Enrollment target
NCT01237379 is a clinical trial that has completed, run by University of Cincinnati. The registered enrollment target is 80 participants.
The verdict
NCT01237379 has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to screen for peroxisome defects in child and adolescent offspring of Bipolar Disorder I (BD-I) parents at different stages of risk for transitioning to mania and following the onset of mania. Prediction 1: Youth with an elevated risk for developing BD-I and first-episode manic patients will exhibit graded deficits in measures of peroxisomal function compared with healthy controls. Prediction 2: Indices of peroxisomal function will be correlated with Red Blood Cells Docosahexaenoic acid (DHA) composition. Prediction 3: Graded deficits in measures of peroxisomal function will be inversely correlated with manic and depression symptom severity scores.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01237379
The ClinicalTrials.gov registry entry for NCT01237379 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01237379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01237379 about?
NCT01237379 is a clinical study titled "Peroxisomal Defects and Familial Risk for Bipolar Disorder". The purpose of this study is to screen for peroxisome defects in child and adolescent offspring of Bipolar Disorder I (BD-I) parents at different stages of risk for transitioning to mania and following the onset of mania. Prediction 1: Youth with an elevated risk for developing BD-I and first-episo...
What is the current status of trial NCT01237379?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2010-10. Estimated completion is 2013-10.
Who is sponsoring clinical trial NCT01237379?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.